

A GUIDE TO ELIMINATING LEPROSY AS A PUBLIC HEALTH PROBLEM

Second Edition 1997

The Disease

Diagnosis

Treatment

Patient Care

WC 335
97GU-1
C.2



Action Programme for the Elimination of Leprosy
World Health Organization



RR

WC 335
97 GU-1
e.2


a 64420

This document is not a formal publication of the World Health Organization (WHO), and all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced and translated, in part or in whole, but not for sale nor for use in conjunction with commercial purposes.

The views expressed in documents by named authors are solely the responsibility of those authors.

ACKNOWLEDGEMENT

Support from the Nippon Foundation is acknowledged.



PREFACE TO THE SECOND EDITION

We have never come so close to seeing leprosy conquered. Even though the disease continues to afflict a large number of people, it is now possible to eliminate it as a public health problem. As a result of the very encouraging results from 10 years' intensive use of treatment based on a combination of antileprosy drugs, known as multidrug therapy (MDT), the World Health Assembly in 1991 resolved to eliminate leprosy as a public health problem by the year 2000. Later, a WHO Working Group on Leprosy outlined the strategy

for eliminating the disease and, since then, practically all the major endemic countries have implemented action plans to eliminate the disease.

The central part of the elimination strategy is to make the WHO-recommended MDT accessible to all patients, including those living in difficult to reach areas and populations.

The purpose of this Guide is to enable every health worker in endemic countries to contribute to the historic task of reaching all leprosy patients with MDT and attaining the goal of eliminating leprosy as a public health problem. Although the Guide is

likely to be useful for health workers at all levels, it is targeted mainly at those who have responsibilities for organizing and implementing leprosy work in the field. It can be used both as self-learning material as well as material for training courses.

The Guide aims to give a clear picture of what needs to be done to implement MDT and attain the elimination goal. It does not attempt to cover every aspect of the disease and is certainly not meant to replace textbooks on leprosy. Only the most important concepts are discussed and details of action to be taken, including

technical steps, are given. Users may refer to the documents listed at the end of the Guide for further information.

Dr S. K. Noordeen

Director

*Action Programme for the Elimination
of Leprosy (LEP)*

WHO, Geneva

CONTENTS

The disease: Leprosy	1	Diagnosis of leprosy	17
Epidemiology: Some facts	2	A case of leprosy	17
Importance of the problem	3	Diagnosis	18
In the past	5	Cardinal signs	18
Current situation	6	A simple test for diagnosis	20
Introduction of multidrug therapy (MDT)	7	Ethical responsibility in leprosy diagnosis	21
Advantages of MDT	8	Clinical examination:	22
Eliminating leprosy	10	History of illness	22
Definition	10	Examination for leprosy	23
The Elimination Strategy	12	A suspect case	24
Essential elements of the strategy	13	Referral for diagnosis	25
Accelerated approaches to achieve leprosy elimination.	14		

Classification of leprosy	27	Treatment of leprosy	47
Choosing the appropriate MDT regimen	27	MDT drugs	48
A guide for clinical classification	28	WHO-recommended MDT regimens	
Flow chart for diagnosis and classification	31	Multibacillary leprosy	52
Bacteriological examination	32	Paucibacillary leprosy	54
		Single-lesion Paucibacillary leprosy	56
Organizing diagnostic services	37		
Provision of efficient health services	38	General safeguards for MDT drugs	58
How to increase awareness in the community?	39	Steps in starting a patient on MDT	59
Who is likely to report to the health centre?	42	Completion of treatment and cure	61
		Defaulter management action	63
		Patients with special needs	68
		Points on MDT treatment	71

Management of complications	72	Common problems and actions to be taken	84
Leprosy reactions			
Reversal or type 1 reaction	73		
Treatment of reversal reaction	74	Organizing MDT services	93
A suggested course of prednisolone	75	Updating of registers	93
ENL or type 2 reaction	77	Screening of patients	94
Treatment of ENL reaction	77	Selecting MDT regimen	94
		Preparing treatment register	94
		Delivering MDT to patients	95
Patient care and referral activities	79	Managing MDT supply	96
Patients at risk of developing nerve damage	79	Special situations and solutions	99
How to detect nerve damage?	80	Special drugs	101
Prevention of disabilities	81	Assessing progress with MDT implementation	102
Grading of disabilities	83	Patient Card (sample)	104
		Selected reading material	106

